Back to News
Market Impact: 0.25
FDA Grants Neuren's NNZ-2591 Orphan Drug Designation For Newborn Encephalopathy
Source: Nasdaq
Healthcare & BiotechRegulation & Legislation
The FDA granted orphan drug designation to Neuren Pharmaceuticals’ NNZ-2591 for neonatal hypoxic-ischemic encephalopathy. The designation is a regulatory milestone, not an approval; the article provided no financial figures or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
More News
- Kimberly-Clark closes its acquisition of Tylenol maker Kenvue. What to expect next
- In one of the largest deals in tech history, Marvell buys Lumentum for $115B
- How Trump’s trade policy is handing Asia to Beijing
- RA Capital Management sells $9.13M in Lenz Therapeutics shares
- Karyopharm stock rating cut to neutral by Rodman on bankruptcy
- Apple may try to increase revenue by doing…something with third-party AI apps